Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Investors interested in listening to the company's conference call can do so using this link.
Zevra Therapeutics Stock Performance
Zevra Therapeutics stock traded up $0.05 during midday trading on Friday, hitting $8.10. 310,442 shares of the company were exchanged, compared to its average volume of 391,101. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The business has a fifty day simple moving average of $7.97 and a two-hundred day simple moving average of $8.12. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The firm has a market capitalization of $432.35 million, a PE ratio of -4.11 and a beta of 1.98.
Insider Buying and Selling at Zevra Therapeutics
In other news, CFO R. Laduane Clifton sold 11,000 shares of the company's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares of the company's stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company's stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock valued at $674,176 over the last quarter. 2.40% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
ZVRA has been the subject of a number of analyst reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Cantor Fitzgerald upgraded Zevra Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 29th. Guggenheim set a $21.00 price objective on Zevra Therapeutics and gave the company a "buy" rating in a research report on Tuesday, February 4th. Finally, Canaccord Genuity Group reduced their target price on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Zevra Therapeutics presently has an average rating of "Buy" and a consensus price target of $21.71.
Check Out Our Latest Stock Analysis on ZVRA
Zevra Therapeutics Company Profile
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Further Reading
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
